Infection prevention in patients receiving CAR T-cells

Anya Kerkache — Fri, 26 Feb 2021 14:08:26 +0000

Joshua Hill, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, explores the strategies and recommendations for infection prophylaxis and monitoring in CAR-T patients. Dr Hill discusses antibacterial, antiviral, and antifungal prophylaxis. IV IG is reserved for patients with very low IgG levels and recurrent or severe bacterial infections primarily. Additionally, vaccination strategies post CAR T-cell therapy are debated, including COVID-19 vaccination. This interview took place during the 3rd European CAR T-cell Meeting.

Infectious complications after CAR T-cell therapy

Anya Kerkache — Fri, 26 Feb 2021 14:08:26 +0000

Joshua Hill, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses infectious complications in patients receiving CAR T-cell therapy. In the first month after CAR T-cell therapy, most infections are bacterial, and the biggest risk factor appears to be severe cytokine release syndrome (CRS). At later time points, the incidence of infections decreases, and patients predominantly have respiratory virus infections. Furthermore, Dr Hill outlines infection prevention strategies such as vaccination and administration of IVIG supplementation. This interview took place during the 3rd European CAR T-cell Meeting.

Joshua Hill – VJRegenMed

Infection prevention in patients receiving CAR T-cells

Infectious complications after CAR T-cell therapy